LNF1901 Monoclonal Antibody Injection
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Malignant Tumors
Conditions
Advanced Malignant Tumors
Trial Timeline
Feb 1, 2024 → Feb 1, 2027
NCT ID
NCT06226363About LNF1901 Monoclonal Antibody Injection
LNF1901 Monoclonal Antibody Injection is a phase 1 stage product being developed by Sun Pharmaceutical for Advanced Malignant Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06226363. Target conditions include Advanced Malignant Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Malignant Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06226363 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Malignant Tumors